Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Adar Zinger"'
Autor:
Lev Lichtenstein, Benjamin Koslowsky, Ami Ben Ya’acov, Irit Avni-Biron, Baruch Ovadia, Ofer Ben-Bassat, Timna Naftali, Uri Kopylov, Yael Haberman, Hagar Banai Eran, Rami Eliakim, Adi Lahat-Zok, Ayal Hirsch, Eran Zittan, Nitsan Maharshak, Matti Waterman, Eran Israeli, Idan Goren, Jacob E. Ollech, Henit Yanai, Bella Ungar, Benjamin Avidan, Dana Ben Hur, Bernardo Melamud, Ori Segol, Zippora Shalem, Iris Dotan, Selwyn H. Odes, Shomron Ben-Horin, Yf’at Snir, Yael Milgrom, Efrat Broide, Eran Goldin, Shmuel Delgado, Yulia Ron, Nathaniel Aviv Cohen, Eran Maoz, Maya Zborovsky, Safwat Odeh, Naim Abu Freha, Eyal Shachar, Yehuda Chowers, Tal Engel, Hila Reiss-Mintz, Arie Segal, Adar Zinger, Ariella Bar-Gil Shitrit
Publikováno v:
Vaccines, Vol 10, Iss 3, p 376 (2022)
Background: Crohn’s disease (CD) and ulcerative colitis (UC) are chronic, immune-mediated inflammatory bowel diseases (IBD) affecting millions of people worldwide. IBD therapies, designed for continuous immune suppression, often render patients mor
Externí odkaz:
https://doaj.org/article/eca69cf35e7040a98fb236c6175f11ed
Autor:
Irit Avni‐Biron, Tali Mishael, Eran Zittan, Moran Livne‐Margolin, Adar Zinger, Roie Tzadok, Rosie Goldenberg, Uri Kopylov, Yulia Ron, Eran Hadar, Sarit Helman, Sorina Grisaru Granovsky, Jacob E. Ollech, Ayelet Arazi, Rivka Farkash, Maor H. Pauker, Henit Yanai, Iris Dotan, Ariella Bar‐Gil Shitrit
Publikováno v:
Alimentary Pharmacology & Therapeutics. 56:1361-1369
Women with inflammatory bowel diseases (IBD) often receive biologics to maintain remission during pregnancy.To assess maternal and neonatal outcomes in patients with IBD treated with ustekinumab (UST) during pregnancy METHODS: In a multicentre, prosp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b95e4e4500699a98327a25bfbd3af71
https://doi.org/10.1111/apt.17224
https://doi.org/10.1111/apt.17224
Autor:
Ela Elyada, Shahaf May, Irit Snir-Alkalay, Eli Pikarsky, Thorsten Stiewe, Marco Mernberger, Audrey Lasry, Yinon Ben-Neriah, Gitit Vaalani, Avanthika Venkatachalam, Adar Zinger, Maya Shaham, Eliran Kadosh, Moshe Oren
Publikováno v:
Nature. 586:133-138
Somatic mutations in p53, which inactivate the tumour-suppressor function of p53 and often confer oncogenic gain-of-function properties, are very common in cancer1,2. Here we studied the effects of hotspot gain-of-function mutations in Trp53 (the gen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::941b7d7691ae146b7bb25248ad38a5e3
https://doi.org/10.1038/s41586-020-2541-0
https://doi.org/10.1038/s41586-020-2541-0
Autor:
Irit Avni-Biron, Tali Mishael, Eran Zittan, Moran Livne, Adar Zinger, Roie Tzadok, Rosalind Goldenberg, Uri Kopylov, Yulia Ron, Eran Hadar, Sarit Helman, Jacob Ollech, Farkash Rivka, Maor H.Pauker, Henit A. Yanai, Iris Dotan, Ariella Bar-Gil Shitrit
Publikováno v:
Gastroenterology. 162:S-632
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed2edae4fe9e95ee403b1d9ef6bdc595
https://doi.org/10.1016/s0016-5085(22)61486-0
https://doi.org/10.1016/s0016-5085(22)61486-0
Publikováno v:
The Israel Medical Association journal : IMAJ. 21(4)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9aaa4e6a53743a015fc3d084aedc3d1e
https://pubmed.ncbi.nlm.nih.gov/31032576
https://pubmed.ncbi.nlm.nih.gov/31032576
Autor:
Eliran, Kadosh, Irit, Snir-Alkalay, Avanthika, Venkatachalam, Shahaf, May, Audrey, Lasry, Ela, Elyada, Adar, Zinger, Maya, Shaham, Gitit, Vaalani, Marco, Mernberger, Thorsten, Stiewe, Eli, Pikarsky, Moshe, Oren, Yinon, Ben-Neriah
Publikováno v:
Signal Transduction and Targeted Therapy
Somatic mutations in p53, which inactivate the tumour-suppressor function of p53 and often confer oncogenic gain-of-function properties, are very common in cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::166556ade4d8fb977c4908a5d96894e4
https://pubmed.ncbi.nlm.nih.gov/33037184
https://pubmed.ncbi.nlm.nih.gov/33037184
Publikováno v:
Nature Immunology. 17:230-240
Inflammation is emerging as one of the hallmarks of cancer, yet its role in most tumors remains unclear. Whereas a minority of solid tumors are associated with overt inflammation, long-term treatment with non-steroidal anti-inflammatory drugs is rema
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::135abe4e5a32df368de8d06497835558
https://doi.org/10.1038/ni.3384
https://doi.org/10.1038/ni.3384
Autor:
Yaarit Ribak, Aya Khalaila, Adar Zinger, Amit Nahum, Oded Shamriz, Yuval Tal, Vardiella Meiner, Eli C. Lewis, Ronen Schuster, Nofar Marcus
Publikováno v:
Clinical Immunology. 212:108249
Genetic aberrations in the toll-like receptor (TLR)3 pathway are associated with increased susceptibility to herpes simplex virus (HSV) infections. Leucine-rich repeat and PYD-containing protein (NLRP)12 is a component of the inflammasome apparatus,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33f828c4cc1e60a57926d958b0a73adc
https://doi.org/10.1016/j.clim.2019.108249
https://doi.org/10.1016/j.clim.2019.108249
Autor:
Guy Brachya, Yinon Ben-Neriah, Moshe Oren, Liran I. Shlush, Itay Omer, Amitai Rivlin, Robert W. Sullivan, Eli Pikarsky, Nathali Kaushansky, Li Dansu, Adar Zinger, Frank Mercurio, Ross L. Levine, Eitan Winter, Waleed Minzel, Ido Burstain, Avanthika Venkatachalam, Joseph Vacca, Leah Fung, Eric Hung, Maya Shaham, Irit Snir-Alkalay, Avner Fink, Paul Erdman, Shlomo Elias
Summary CKIα ablation induces p53 activation, and CKIα degradation underlies the therapeutic effect of lenalidomide in a pre-leukemia syndrome. Here we describe the development of CKIα inhibitors, which co-target the transcriptional kinases CDK7 a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2440625cc9c49007ec76bcf64decbae
https://europepmc.org/articles/PMC6701634/
https://europepmc.org/articles/PMC6701634/
Publikováno v:
Diabetes/Metabolism Research and Reviews. 30:88-95
Type 2 diabetes mellitus is very prevalent among persons aged 60-80 years old. This population is expected to increase in number and is characterized by the presence of comorbidities, long standing diabetes, frailty, high rate of cognitive impairment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4364aa59846939f704116a35c2a3aadb
https://doi.org/10.1002/dmrr.2485
https://doi.org/10.1002/dmrr.2485